Human Genome Sciences Recent News
Piper Jaffray Raises PT On Human Genome Sciences To $36
J.P. Morgan Maintains Overweight on Human Genome Sciences (HGSI)
J.P. Morgan Reiterates OW Rating On HGSI
Goldman Sachs Raises HGSI Target From $25 To $28
Piper Jaffray Comments On Benlysta Approval (HGSI)
Piper Jaffray Lowers PT On Human Genome Sciences
Human Genome Sciences Trading Up 1.53%
FDA Delays PDUFA on HGSI's Benlysta (HGSI)
J.P. Morgan Reiterates Human Genome Sciences OW Rating
Ford & Human Genome Calls Active (HGSI)
Phase 3 Of Epratuzumab Expected To Commence By Year End
HGSI Removed From Citigroup's Top Picks Live! List
Human Genome Sciences (HGSI) and Novartis (NVS) Hepatitis Treatment Awaits Approval
J.P. Morgan Maintains Human Genome Sciences (HGSI) Overweight Rating